ECCO 2024

Are all JAKies the same?

The quest for predictive markers goes on...

S1P-Modulators from a safety perspective

Real-world data from a H2H-study on Vedolizumab vs. Tofacitinib in UC

Primary sclerosing cholangitis – lessons from a large PSC-IBD registry

Cell-based therapies: The end of the story or the bright future?

Combination of different drug classes - risks and benefits

A spotlight on the PROFILE study

Treatment targets in 2024 - a silent revolution

Finally here: controlled trials in surgery!

Mirikizumab in CD

IL-23 in UC

Ustekinumab first, anti-p19 second?

Next chapter in S1P- and JAK-inhibition

Obefazimod & IL23R-CAR-Tregs - new molecules in focus

Results of the phase II PIZZICATO (ritlecitinib & brepocitinib) in Crohn's disease

Mirikizumab in crohn's disease

Mirikizumab vs Ustekinumab

Changing the PROFILE of how we treat CD

VIVID 1: Mirikizumab in Crohn's Disease

Darvadstrocel for complex perianal fistulas and Crohn’s Disease

Tregs - a treatment for the future?

PIZZICATO - new JAKies for crohn's disease

VIVID 1: Comparison of mirikizumab with ustekinumab in Crohn’s disease

Mirikizumab in moderate to severe Crohn’s disease: overall assessment of the VIVID-1 trial

VIVID 1- Comparação do Mirikizumab com o Ustecinumab na Doença de Crohn

PIZZICATO - neue JAKs für Morbus Crohn

Mirikizumab στη θεραπεία της μέτριας προς βαρειά NC: Συνολική ανάλυση μελέτης Vivid-1

Mirikizumab vs Ustekinumab

Mirikizumab bei Morbus Crohn

Resultaten van de fase 2 PIZZICATO (ritlecitinib & brepocitinib) studie in ziekte van Crohn

The efficacy of biologics and small molecules in microscopic colitis – an ECCO Confer Cases study results

Risankizumab & guselkumab in ulcerative colitis

Long term outcome of Obefazimod in UC

VTX-002 in patients with moderate to severe UC

Mirikizumab in anti-TNF failures with UC

VTX002 (S1P-modulator) & obefazimod in ulcerative colitis

VTX-002 in pazienti con colite ulcerosa da moderata a grave

Risankizumab & Guselkumab bei Colitis Ulcerosa

lange-termijns uitkomst van obefazimod in UC

VTX002 (S1P-Modulator) & Obefazimod bei Colitis Ulcerosa

Leki biologiczne i małocząsteczkowe w terapii mikroskopowych zapaleń jelit – wnioski z badania ECCO Confer Cases

Comparability examination between SB17 and Ustekimumab originator

Therapy in transition

Still a long road ahead in standards of care in IBD – the results of an E-QUALITY survey

Esame di comparabilità tra SP17 e ustekimumab originator

Marzenia a rzeczywistość – wyniki ankiety E-QUALITY na temat standardów opieki w IBD

Therapie im Umbruch

PROFILE: practice-changing results

Biomarker for biological loss of response in CD?

Allogenic mesenchymal stem cells for complex fistula in CD: End of the story?

PROFILE: Biomarkers not successfull for therapy prediction

Should we proactively treat CD-patients having small bowel lesions on capsules?

Early intervention in Crohn´s disease therapy

Results from the PROFILE-trial

Changing treatment paradigm in CD

Risultati dallo studio PROFILE

Injection de cellules souches mesenchimateuses allogéniques dans les fistules complexes de la maladie de Crohn: Fin de l'histoire?

PROFILE: Biomarker nicht erfolgreich zur Prädiktion der Therapieantwort

Biomarker for biological loss of response in CD?

Intervenção terapêutica precoce na doença de Crohn

Cambiano i paradigmi di trattamento nelle malattie di crohn

Faut-il traiter les patients avec les lesions de Crohn en videocapsules?

Guselkumab & Golimumab have complementary effects when given together

Towards the proactive management of AS-UC responding to IB-steroids

Vers un traitement plus agressif de la colite aigüe grave cortico-sensible

Guselkumab & Golimumab ont des effets complémentaires lorqu'ils sont associés

HD-WLE with segmental reinspection is not inferior to HD-dye-based CE in detecting colorectal neoplasia in IBD

Immunohomeostasis by regulatory CAR-T cells!?

Therapy in transition

Personalized treatment in IBD: reality or hype?

Use of CAR-Tregs in IBD: preclinical data

Therapie im Umbruch

gepersonaliseerde aanpak van IBD: realiteit of hype?

HD-WLE με επανεξέταση των τμημάτων δεν υπολείπεται της χρωμοενδοσκόπησης στην ανίχνευση νεοπλασίας στο παχύ έντερο στις ΙΦΝΕ

Utilizzo di cellule CAR Tregs nelle MICI: dati preclinici

Immunohomöstase durch regulatorische CAR-T-Zellen!?

Colectomy and the natural history of PSC – lessons form a large PSC-IBD registry

Extended mesenterectomy is not superior to mesenteric sparing resection to prevent postoperative recurrence of CD

MIRACLE project: Avoidance of protective Ileostomy

Randomised clinical trials finally coming to IBD surgery!

Implication of proctocolectomy in patients affected by UC

No changes to surgical techniques for ileosecal disection in CD

End of the Kono-S legend!

Kolektomia a historia naturalna PSC – czy istnieje zależność?

Implicazioni della proctocolectomia in pazienti affetti da colite ulcerosa

Η εκτεταμένη εκτομή του μεσεντερίου δεν υπερέχει της διατήρησής του για την πρόληψη της μετεγχειρητικής νόσου του Crohn

La fin de la legende du Kono-S!

MIRACLE-Projekt: Verzicht auf protektive Ileostomie

Los ensayos clínicos aleatorizados llegan a la cirugía de las EII

Molecular healing, our next goal?

Cicatrización molecular: nuestro próximo objetivo?

Molecular effects of IL-23p19 blockade

Transcriptomic profiles in patients with UC receiving filgotinib

Análise do Transcriptoma em doentes com colite ulcerosa tratados com Filgotinib

Molekulare Effekte der IL-23p19-Blockade

Diet & Lifestyle: Keys for the management of IBD!

Diet & Lifestyle: Keys for the management of IBD!